海森药业

Zhejiang Haisen Pharmaceutical Co., Ltd. is located in Liushi street, Dongyang city Zhejiang province. It is a medium scale enterprise which mainly engages in the R&D, production and operation of API and pharmaceutical intermediates. It is a state hi-tech enterprise, covering an area of 70,000 square meters and with fixed capital of RMB 230 million and over 450 employees including 32% professional technicians.

The company passed ISO9001:2000 international quality system certification in 2001.In 2006, it passed the GMP certification for the first time in China. In the same year, it obtained the CEP certificate of EU. In 2014, it passed the on-site audit of FDA for the first time in the US.

The main products of the company are API: Saccharide, Analgin, Pazufloxacin mesylate, Atorvastatin Calcium, Paroxetine Hydrochloride, Escitalopram Oxalate;Intermediates: PHBA, methylparoxetine, etc.At present, many varieties have been registered in the United States, the European Union, Japan, South Korea, India, Brazil, Mexico and other countries.Among them, sucrose and aluminum products occupy more than 60% of the world market.

Adhering to the quality and environment policy of "customer first, environment first, quality leading, continuous improvement", the company continues to increase the research and development of high-tech and investment efforts, from which more economic benefits and growth points.Company and the sichuan antibiotic industrial research institute, Shanghai medical professionals hospital, tianjin drug research institute, zhejiang university and other research institutions established good long-term cooperative relations for many years, zhejiang provincial technology center, member of hazen drug research institute of zhejiang province and hazen pharmaceutical experts workstation has formed, the company leading domestic technology center of research and development level has reached with the field.Escitalopram oxalate tablets (trademark Taqi), jointly developed by Zhejiang Hisen Pharmaceutical Co., Ltd. and Zhejiang Jinhua Kangenbei Biological Pharmaceutical Co., Ltd., has been listed. Hisen Pharmaceutical will arrange national sales and invite investment, and welcome cooperation and development.

The company adheres to the development of good faith. Since its establishment, it has been named by the municipal government as "contract and trustworthy enterprise", "civilized unit" and "AAA" credit enterprise of the bank for many years, which keeps a good social reputation.The leadership of the company has always listed environmental protection as the main task of development. At present, the company has invested tens of millions of yuan in the construction of environmental protection engineering, and constantly promoted the standard emission of "three wastes" to a new height.The company's interior buildings are strewn at random and lined with trees.According to the guidance of the company's long-term development goals, our company will, as always, take the international market as the guide, rely on technological innovation, management innovation, give full play to their own advantages, wholeheartedly to provide customers with more quality products and quality services, and constantly improve the overall strength of the company.And willing to cooperate with friends from all walks of life, common development.